5 Followers on Owler

Cardiorentis

Cardiorentis is a biopharmaceutical company designed for drug development. Read more

Johannes Holzmeister's photo - Chairman & CEO of Cardiorentis

Chairman & CEO

Johannes Holzmeister

CEO Approval Rating

69/100

Founded:

2010

Status:

PrivateIndependent Company

Est. Annual Revenue
Est. Employees
Sector

Update Industry
Headquarters

CARDIORENTIS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Vericel is one of Cardiorentis's top competitors. Vericel is a Public company that was founded in Cambridge, Massachusetts in 1989. Vericel is in the Pharmaceuticals field. Vericel has 273 more employees vs. Cardiorentis.

Cesca is perceived as one of Cardiorentis's biggest rivals. Cesca was founded in 1986 in Rancho Cordova, California. Cesca operates in the Biotechnology industry. Cesca generates $13.1M more revenue than Cardiorentis.

Osiris Therapeutics is a top competitor of Cardiorentis. Osiris Therapeutics's headquarters is in Columbia, Maryland, and was founded in 1992. Osiris Therapeutics competes in the Health Care Equipment field. Osiris Therapeutics generates ∞% of Cardiorentis's revenue.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 0 a good estimate for Cardiorentis's Employee count?

Cardiorentis Acquisitions

No recent acquisitions found related to Cardiorentis

Cardiorentis Funding History

Since Cardiorentis was founded in 2010, it has participated in 2 rounds of funding. In total Cardiorentis has raised $118.3M. Cardiorentis' last funding round was on Jan 2016 for a total of $60.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series B
Jan 2016
$60M
-
Unattributed
Sep 2014
$58.3M

HealthCare Royalty Partners II, L.P.

Since Cardiorentis was founded in 2010, it has participated in 2 rounds of funding. In total Cardiorentis has raised $118.3M. Cardiorentis' last funding round was on Jan 2016 for a total of $60.0M

Cardiorentis Investments

No recent investments found related to Cardiorentis

Cardiorentis News

January 12, 2016FierceBiotechIT

Cardiorentis raises $60M as PhIII heart failure trial nears completion

Cardiorentis has raised CHF 60 million ($60 million). The investment bolsters the biotech's bank bala... See more »
January 11, 2016The Pharma Letter

Cardiorentis raises $60 million to fund development of heart failure treatment; names new CFO

Switzerland-based Cardiorentis AG said it has raised 60 million Swiss Franc ($60 million) via private... See more »
May 25, 2015BIOPORTFOLIO

Cardiorentis completes patient enrollment in Phase III trial of heart failure drug Ularitide

Swiss biopharmaceutical firm Cardiorentis has completed patient enrollment in its pivotal Phase III c... See more »

Cardiorentis Press Releases

Social Media

Cardiorentis Headquarters

Steinhauserstrasse 74

Zug, Zug6300

41-41-748-60-30

Driving Directions »

Trending Companies

Cardiorentis Summary

ABOUT

Overview

Cardiorentis is a biopharmaceutical company designed for drug development. Cardiorentis was founded in 2010. Cardiorentis' headquarters is located in Zug, Zug, CH 6300. It has raised 118.3M in 2 rounds. The latest round was in Jan 2016. Cardiorentis' ...

CEO

Cardiorentis's Chairman & CEO, Johannes Holzmeister, currently has an approval rating of 69%. Cardiorentis's primary competitors are Vericel, Cesca & Osiris Therapeutics.

Frequently Asked Questions about Cardiorentis

  1. When was Cardiorentis founded?

    Cardiorentis was founded in 2010
  2. Who is Cardiorentis's CEO?

    Cardiorentis's CEO is Johannes Holzmeister
  3. How much revenue does Cardiorentis generate?

    Cardiorentis generates $ < 1M in revenue
  4. How much funding does Cardiorentis have?

    Cardiorentis has historically raised $118.3M in funding
  1. Where is Cardiorentis's headquarters?

    Cardiorentis's headquarters is in Zug Zug, CH
  2. How many employees does Cardiorentis have?

    Cardiorentis has 0 employees
  3. Who are Cardiorentis's competitors?

    Cardiorentis's top competitors are Vericel, Cesca, Osiris Therapeutics